July/August 2023: Second-Line Switch to Dolutegravir for Treatment of HIV Infection

Aug 23, 2023

Article and Study Summary: Second-Line Switch to Dolutegravir for Treatment of HIV Infection Published in: N Engl J Med. 2023;388(25):2349-2359 https://www.nejm.org/doi/full/10.1056/NEJMoa2210005 Authors: Ombajo LA, Penner J, Nkuranga J, et al. Summary The...

Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations

Jul 24, 2023

Authors:Nyaradzo M. Mgodi, Grant Murewanhema, Enos Moyo, Chesterfield Samba, Godfrey Musuka, Tafadzwa Dzinamarira, Joelle M. BrownAbstract: Introduction The burden of HIV in sub-Saharan Africa (SSA) remains unacceptably high, and disproportionately affects girls and...

Invisible, but not absent

Jul 19, 2023

Authors: Kevin M De Cock, Wafaa M El-Sadr Abstract: Named lectures invite wide-ranging reflections relevant to contributions of persons most often no longer with us. This commentary is stimulated by a recent lecture honoring two people who helped shape the HIV...

Person-centred, integrated non-communicable disease and HIV decentralized drug distribution in Eswatini and South Africa: outcomes and challenges

Jul 6, 2023

Authors: Deborah Goldstein, Nathan Ford, Nicholas Kisyeri, Maggie Munsamy, Lirica Nishimoto, Kufor Osi, Herve Kambale, Thomas Minior, Moses Bateganya Abstract: Introduction: Non-communicable diseases (NCDs) are highly prevalent in people living with HIV above 50...

Contraception and intersection with HIV services in 11 high HIV burden sub-Saharan African countries: Results from the population-based HIV Impact Assessment cross-sectional studies conducted from 2015 to 2018

Jul 5, 2023

Authors: Chelsea Solmo, Katharine A. Yuengling, Michael L. Cooney, Karampreet Sachathep, Sarah Ayton, Neena Phillip, Abigail Greenleaf, Elizabeth Gummerson, Nora Hennesy, Sileshi Lulseged, Dereje Habt, Magreth Kagashe, John H. Rogers, Wilford Kirungi, Katherine...

HIV